ABSTRACT. Metachondromatosis is a rare disorder of autosomal inheritance with incomplete penetrance, which is characterized by formation of osteochondroma and enchondroma, caused by loss of function of the protein tyrosine phosphatase nonreceptor type 11 (PTPN11) gene. Diagnosis is made based on the distribution and orientation of lesions with history of regression of lesions with time and confirmed by genetic mutation of PTPN11 gene. We report a rare case of a 24-year-old male with Alport's syndrome with metachondromatosis due to missense variation in PTPN11 gene.
Introduction
Metachondromatosis is a rare genetic disease of osteochondroma and enchondroma formation, caused by loss of function of the protein tyrosine phosphatase nonreceptor type 11 (PTPN11) gene. [1] [2] [3] [4] [5] [6] [7] Loss of function of the PTPN11 tumor suppressor gene has been identified as a cause, and the condition is inherited in an autosomal-dominant pattern with incomplete penetrance unlike other enchondromatoses, such as Ollier's disease and Maffucci syndrome, which are sporadic in nature. It is Correspondence to:
Dr. Sudhir Mehta, Department of Nephrology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India. E-mail: samsudhir123@yahoo.co.in distinct from multiple osteochondromatosis (MO), also known as hereditary multiple exocytosis, since the orientation of lesions in metachondromatosis is toward, rather than away from, the epiphysis, and there is a predilection for the hands and feet. 8 Diagnosis is made based on the distribution and orientation of lesions with history of regression of lesions with time and confirmed by genetic mutation of PTPN11 gene. Association of metachondromatosis with Alport's syndrome has not been reported in the past. We report a rare case of a 24-year-old male with Alport's syndrome having hemizygous 5' splice mutation in intron 10 of COL4A5 gene with multiple bony swellings suggestive of metachondromatosis due to missense variation in PTPN11 gene.
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Case Report
Informed consent was obtained from the patient before presenting the report. A 24-year-old male, born of nonconsanguineous marriage with normal birth and developmental history, was admitted to us for evaluation of deranged renal function. The patient had a history of recurrent microscopic hematuria since late childhood. He developed normally till the age of three years when the parents first noticed bony swelling over long bones of both upper and lower limbs, which gradually increased initially, but later on shown some regression in late second decade of life. These bony swellings never interfered with growth of child, and hence, no consultation was taken for this. He also had history of hearing loss since late childhood. Initial renal functions were normal. He was admitted with complaints of anorexia, nausea, vomiting, generalized fatigue, and pallor for the last four months. His first creatinine report was 11.86 mg/dL. His vitals were normal, and the blood pressure was 140/86 mm Hg. His height was normal and build was thin. The general physical examination showed pallor and mild pedal edema up to the ankle. There were bony swellings near the ends of long bones of approximately 3-4 cm of both upper and lower limbs (Figures 1-3 ). The ocular examination was suggestive of lenticonus in both eyes. The ear-nose-throat evaluation was suggestive of bilateral sensor neural hearing loss. There were crepitations in both chest fields with the remaining systemic examination being normal. At presentation, his investigations were hemoglobin of 5.6 g/dL, total leukocyte count of 9300 (N 80%, L 12%, M 6%, E 1%, B 1%), platelet 1.53 lakh, blood urea 143, serum creatinine 11.8 mg/dL, sodium 137 mmol/L, potassium 5.5 mmol/L, total protein 7.8 mg/dL, albumin 3.9 mg/dL, total bilirubin 0.29 mg/dL, direct 3.9 mg/dL, oxaloacetate transaminase 15 U/L, pyruvate transaminase 9 U/L, alkaline phosphate 101 U/L, calcium 8.5 mg/dL, phosphorus 4.9 mg/dL, uric acid 10.1 mg/dL, parathormone 21 pg/mL, serum iron 34.7 µg/dL, total iron binding capacity 249 µg/dL, and transferrin saturation of 13.9%. Viral markers were nonreactive. Urine routine showed 2+ proteinuria and 30-40 RBC/hpf and spot urine protein-creatinine ratio of seven. Patient was conservatively treated with hemodialysis (HD) sessions and symptomatic treatment. Ultrasonography of the abdomen was suggestive of small kidneys with increased echogenicity and loss of corticomedullary differentiation suggestive of chronic kidney disease (CKD). Two-dimensional echo was suggestive of DCMP with ejection fraction of 26%. In view of positive findings of sensorineural hearing loss, bilateral lentic onus, and underlying CKD, possibility of Alport's syndrome was made. His genetic analysis was done, which was suggestive of homozygous 5' splice mutation in intron 10 of COL4A5 gene that affects invariant GT donor splice site exon 10. This was reported as pathological variant. There is another indel variation in exon 45 of COL4A3 gene that results in stop codon and premature truncation of the protein at codon 1331, but this variant was of uncertain significance. This was confirmed with Sanger sequencing. The patient was further evaluated for the bony swellings. His history and clinical findings were likely suggestive of metachondromatosis. The genetic analysis done was suggestive of heterozygous missense variation in PTPN11 gene. Literature was reviewed for metachondromatosis and its association, but no case report of metachondromatosis was found in association with Alport's syndrome. This is probably the first reported case of metachondromatosis in association with Alport's syndrome. The patient is now under regular follow-up and on regular maintenance HD thrice a week and doing well with good compliance. 
Discussion
Metachondromatosis is a rare genetic disorder causing a combination of osteochondromas and enchondromas in the hands, feet, long bones, iliac crests, and spine. Diagnosis is made based on the distribution and orientation of lesions; however, a recently published case report describes a family with radiographic features of both metachondromatosis and MO and a mutation of EXT-2. 9 Lesions in metachondromatosis are reportedly not associated with axial deformity or disruption to the growth of bones; however, case reports have documented deformities in fingers and the distal tibia. Per articular soft tissue calcifications are often present and appear similar to those seen in Trevor's disease, also known as dysplasia epiphysealis hemimelica. Lesions are typically present in the hands and feet; however, the iliac crest spine and long bones such as the proximal femur are also affected. The natural history of metachondromatosis is described as one of the spontaneous regressions during childhood although some lesions persist into adulthood. 10 As with other enchondromatoses and MO, new lesions do not appear after skeletal maturation. 11 Taking a thorough family history of spontaneously regressing lesions is, therefore, vital in the diagnosis of metachondromatosis. The differential diagnosis includes MO and multiple enchondromatosis (Ollier's disease). The orientation of lesions toward rather than away from epiphyses helps distinguish metachondromatosis from MO. Lesions associated with Ollier's disease are almost always unilateral, and there is no familial inheritance of the condition, unlike metachondromatosis. The prevalence of multiple osteochondromas is estimated to be 2/100,000 and Ollier's disease 1/100,000. 12, 13 Both conditions are, therefore, significantly more prevalent than metachondromatosis. This condition is also considered to differ from other enchondromatoses due to its lack of potential for malignant transformation; however, a recent paper reports a grade two chondrosarcoma arising in an enchondroma in a patient with metachondromatosis. Other reported complications of metachondromatosis include common peroneal nerve palsy secondary to compression by exostoses near the fibular head, resulting in numbness and foot drop. Nerve function usually recovers completely with excision of the offending lesion. Avascular necrosis of the femoral head has also been described in patients with lesions around the femoral neck. This is thought to be due to the disruption of lateral epiphyseal vessels in the femoral neck. Necrosis of skin overlying a large lesion has occurred in at least one case. Two studies have independently identified loss of function of the PTPN11 gene as a cause of metachondromatosis in 13 of 19 families, further distinguishing this disorder from MO and Ollier's disease. 14, 15 Several other overlapping but phenotypically distinct disorders, including Noonan syndrome, Noonan-like disorder with multiple giant cell lesion syndrome, and LEOPARD syndrome, are caused by gain of function mutations of PTPN11. Histopathological findings differ between authors. Several papers found typical enchondromas and osteochondromas with cartilaginous caps; however, one paper reported lesions with fibrous caps overlying cartilaginous cores. The reason for the difference in these findings is unclear. Bowen et al reviewed the histopathologic features of 30 exostoses excised from patients with MO and compared them with 15 lesions excised from children with metachondromatosis. 15 They found lesions in MO to be comprised of cartilaginous caps overlying endochondral bone immediately beneath, whereas lesions in children with metachondromatosis had a fibrous cap, a disorganized cartilaginous core, and surrounding trabecular bone. Two studies have attempted to identify the gene responsible for metachondromatosis. Sobreira et al studied two families, finding an 11 base pair deletion in one and a nonsense mutation in the other, both (100%) resulting in loss of function of the PTPN11 gene. 14 Bowen et al studied 17 families, of which frame shift, nonsense, deletion, and splice site mutations of PTPN11 were identified in 11 (65 %). 15 This is distinct from the EXT-1 and EXT-2 gene mutations that cause MO. Cells appear to undergo a "second hit," as in MO, resulting in two nonfunctioning PTPN11 genes, leading to the absence of the production of the SHP2 protein. The mechanism by which SHP2 deficiency leads to the development of enchondroma or osteochondroma is yet to be determined. Formal treatment and surveillance recommendations are difficult to make in the absence of a larger number of case reports in the literature. A conservative approach, however, appears to be warranted. Indications for surgical excision are predominantly symptomatic, relating to pain and nerve compression. Malignant transformation has only recently been described but should be considered an indication for intervention. Based on observations of other conditions causing the formation of enchondromas and osteochondromas, regular biannual clinical review, skeletal survey of regions not examinable clinically (chest, pelvis, and scapula), and repeat imaging of lesions that grow larger or become painful appear appropriate, with a view to minimizing unnecessary irradiation. Hence, the presence of multiple bony swellings near epiphysis of long bones with characteristic distribution pattern with history of regression should prompt the possibility of metachondromatosis. The diagnosis should be confirmed by genetic analysis by mutation of PTPN11 gene. This is one of the rare case reports of metachondromatosis reported in the patient of genetically confirmed Alport's syndrome.
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